Pharmaceutical Investing Ironwood and Alnylam Enter US GI Disease Education and Promotional Agreement
Pharmaceutical Investing Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
Arbutus’ LNP Licensee Alnylam Announces FDA Approval of ONPATTRO (patisiran), for the Treatment of ATTR Amyloidosis
SAGA Metals Extends Claims at the Radar Ti-V-Fe Project --Securing the Entire Titanomagnetite-Bearing Intrusion
Significant intercepts of gold and copper show Golden Eye emerging as a highly promising new resource prospect
Alvopetro Announces an Operational Update, Q1 2025 Financial Results and Details for our Upcoming AGM
